TACE plus systemic therapy in advanced hepatocellular carcinoma: a comparison of lenvatinib and donafenib
Abstract
BackgroundTo evaluate transcatheter arterial chemoembolization (TACE) combined with systemic therapy versus TACE monotherapy in advanced hepatocellular carcinoma (HCC), and to compare the efficacies of lenvatinib and donafenib when combined with TACE and immune checkpoint inhibitors (ICIs).MethodsThis retrospective study included 176 patients with advanced HCC receiving initial TACE, categorized into combination therapy (n = 128) or TACE monotherapy (n = 48) groups. A subgroup analysis compared TACE plus ICIs combined with lenvatinib (n = 78) or donafenib (n = 33). Propensity score matching (PSM) was utilized to minimize baseline confounding variables. Progression-free survival (PFS) and overall survival (OS) were analyzed.ResultsCombination therapy achieved a significantly higher objective treatment effective rate than monotherapy (75.0% vs. 41.7%, P < 0.001), with significantly prolonged PFS and OS, a benefit maintained after PSM. Among the specific regimens, the lenvatinib-based combination yielded a higher objective effective rate than donafenib (83.3% vs. 63.6%, P = 0.023). Post-PSM, the lenvatinib group maintained a significant PFS advantage (P = 0.007), while OS showed a marginal trend toward improvement (P = 0.057). Multivariate analysis identified treatment without combined systemic therapy and ineffective treatment response as independent predictors of inferior OS. Severe TACE-related adverse events (Grade 3/4) were comparable between combination and monotherapy cohorts (18.8% vs. 14.6%, P = 0.518), as well as between the lenvatinib and donafenib subgroups (21.8% vs. 15.2%, P = 0.422).ConclusionTACE combined with systemic therapy significantly improves clinical outcomes in advanced HCC without increasing severe toxicity. Furthermore, the triple therapy of TACE, ICIs, and lenvatinib confers superior PFS and tumor response rates compared to the donafenib-based regimen, along with a trend toward OS improvement that did not reach statistical significance.
Related
- Survival outcomes of spleen-strengthening and dampness-eliminating traditional Chinese medicine granules combined with lenvatinib for unresectable hepatocellular carcinoma: a large-sample retrospective study based on electronic medical records
- Hepatic arterial infusion chemotherapy plus lenvatinib and programmed death receptor 1 inhibitor for hepatocellular carcinoma with portal vein tumor thrombosis: a prospective controlled study
- A Case of Unresectable Hepatocellular Carcinoma Responding to Durvalumab Plus Tremelimumab after Lenvatinib Treatment
- GLP-1 receptor agonist targets an AMPKα1-HIF1α-PFKFB3 metabolic vulnerability and enhances Lenvatinib response in hepatocellular carcinoma
- HuR Confers Resistance of Hepatocellular Carcinoma to Lenvatinib by Inhibiting Ferroptosis
BibTeX
@article{zhang2026tace,
title = {{TACE plus systemic therapy in advanced hepatocellular carcinoma: a comparison of lenvatinib and donafenib}},
author = {Hao Zhang and Ji-Hui Hu and Qing Wang and Bin Lan and Hao-Yu Yan and Zhi-Yong Fang and Hua Xiang and Jie Tan},
journal = {Frontiers in Pharmacology},
year = {2026},
month = nov,
doi = {10.3389/fphar.2026.1972185},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1972185},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - TACE plus systemic therapy in advanced hepatocellular carcinoma: a comparison of lenvatinib and donafenib
AU - Hao Zhang
AU - Ji-Hui Hu
AU - Qing Wang
AU - Bin Lan
AU - Hao-Yu Yan
AU - Zhi-Yong Fang
AU - Hua Xiang
AU - Jie Tan
PY - 2026
DA - 2026/11/09
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1972185
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1972185
AB - BackgroundTo evaluate transcatheter arterial chemoembolization (TACE) combined with systemic therapy versus TACE monotherapy in advanced hepatocellular carcinoma (HCC), and to compare the efficacies of lenvatinib and donafenib when combined with TACE and immune checkpoint inhibitors (ICIs).MethodsThis retrospective study included 176 patients with advanced HCC receiving initial TACE, categorized into combination therapy (n = 128) or TACE monotherapy (n = 48) groups. A subgroup analysis compared TACE plus ICIs combined with lenvatinib (n = 78) or donafenib (n = 33). Propensity score matching (PSM) was utilized to minimize baseline confounding variables. Progression-free survival (PFS) and overall survival (OS) were analyzed.ResultsCombination therapy achieved a significantly higher objective treatment effective rate than monotherapy (75.0% vs. 41.7%, P < 0.001), with significantly prolonged PFS and OS, a benefit maintained after PSM. Among the specific regimens, the lenvatinib-based combination yielded a higher objective effective rate than donafenib (83.3% vs. 63.6%, P = 0.023). Post-PSM, the lenvatinib group maintained a significant PFS advantage (P = 0.007), while OS showed a marginal trend toward improvement (P = 0.057). Multivariate analysis identified treatment without combined systemic therapy and ineffective treatment response as independent predictors of inferior OS. Severe TACE-related adverse events (Grade 3/4) were comparable between combination and monotherapy cohorts (18.8% vs. 14.6%, P = 0.518), as well as between the lenvatinib and donafenib subgroups (21.8% vs. 15.2%, P = 0.422).ConclusionTACE combined with systemic therapy significantly improves clinical outcomes in advanced HCC without increasing severe toxicity. Furthermore, the triple therapy of TACE, ICIs, and lenvatinib confers superior PFS and tumor response rates compared to the donafenib-based regimen, along with a trend toward OS improvement that did not reach statistical significance.
SN - 1663-9812
ER -